Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics

Thrombosis and Haemostasis

Volumn 106, Issue 1, 2011, Pages 20-33

  Thomas, Aurélien ^a,d   Lenglet, Sébastien ^b   Chaurand, Pierre ^c   Déglon, Julien ^a,d   Mangin, Patrice ^a   Mach, François ^b   Steffens, Sabine ^b   Wolfender, Jean Luc ^d   Staub, Christian ^a,d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b University Hospital   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cardiovascular diseases; Imaging mass spectrometry; Lipidomics; Mass spectrometry; Proteomics

Indexed keywords

LIPID; PROTEIN DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GEL; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIPID ANALYSIS; LIPIDOMICS; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEOMICS; QUANTITATIVE DIAGNOSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 79960055910     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-12-0812     Document Type: Review

References (147)

1. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388-2398.
2. American Heart Association: Heart Disease and Stroke Statistics-2008 Update. Dallas, Texas: AHA; 2008.
3. Blankenhorn DH, Hodis HN. Atherosclerosis--reversal with therapy. West J Med 1993; 159: 172-179.
4. Elkind MS. Inflammatory mechanisms of stroke. Stroke 2010; 41 (10 Suppl): S3-8.
5. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001; 104: 503-516.
6. Bucova M, Bernadic M, Buckingham T. C-reactive protein, cytokines and inflammation in cardiovascular diseases. Bratisl Lek Listy 2008; 109: 333-340.
7. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy 2003; 2: 257-265.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
9. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
10. Hansson GK. Atherosclerosis--an immune disease: The Anitschkov Lecture 2007. Atherosclerosis 2009; 202: 2-10.
11. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
12. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007; 26: 51-78.
13. Fiehn O. Metabolomics--the link between genotypes and phenotypes. Plant Mol Biol 2002; 48: 155-171.
14. Boccard J, Veuthey JL, Rudaz S. Knowledge discovery in metabolomics: an overview of MS data handling. J Sep Sci 2010; 33: 290-304.
15. Wolfender JL, Glauser G, Boccard J, et al. MS-based plant metabolomic approaches for biomarker discovery. Nat Prod Commun 2009; 4: 1417-1430.
16. Zhou M, Veenstra T. Mass spectrometry: m/z 1983-2008. Biotechniques 2008; 44: 667-668, 670.
17. Griffiths WJ, Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem Soc Rev 2009; 38: 1882-1896.
18. Shevchenko A, Simons K. Lipidomics: coming to grips with lipid diversity. Nat Rev Mol Cell Biol 2010; 11: 593-598.
19. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006; 312: 212-217.
20. Tunon J, Martin-Ventura JL, Blanco-Colio LM, et al. Proteomic strategies in the search of new biomarkers in atherothrombosis. J Am Coll Cardiol 2010; 55: 2009-2016.
21. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-867.
22. Martinez-Pinna R, Martin-Ventura JL, Mas S, et al. Proteomics in atherosclerosis. Curr Atheroscler Rep 2008; 10: 209-215.
23. Moxon JV, Padula MP, Herbert BR, et al. Challenges, current status and future perspectives of proteomics in improving understanding, diagnosis and treatment of vascular disease. Eur J Vasc Endovasc Surg 2009; 38: 346-355.
24. Barrett J, Brophy PM, Hamilton JV. Analysing proteomic data. Int J Parasitol 2005; 35: 543-553.
25. Mayr M, Zhang J, Greene AS, et al. Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. Mol Cell Proteomics 2006; 5: 1853-1864.
26. Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophoresis and mass spectrometry: strengths and limitations. Trends Analyt Chem 2003; 22: 273-281.
27. Schoenhoff FS, Fu Q, Van Eyk JE. Cardiovascular proteomics: implications for clinical applications. Clin Lab Med 2009; 29: 87-99.
28. Hopfgartner G, Varesio E, Tschappat V, et al. Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules. J Mass Spectrom 2004; 39: 845-855.
29. Chernushevich IV, Loboda AV, Thomson BA. An introduction to quadrupoletime- of-flight mass spectrometry. J Mass Spectrom 2001; 36: 849-865.
30. Perry RH, Cooks RG, Noll RJ. Orbitrap mass spectrometry: instrumentation, ion motion and applications. Mass Spectrom Rev 2008; 27: 661-699.
31. Page JS, Masselon CD, Smith RD. FTICR mass spectrometry for qualitative and quantitative bioanalyses. Curr Opin Biotechnol 2004; 15: 3-11.
32. Gygi SP, Corthals GL, Zhang Y, et al. Evaluation of two-dimensional gel electrophoresis- based proteome analysis technology. Proc Natl Acad Sci USA 2000; 97: 9390-9395.
33. Wilkins MR, Gasteiger E, Sanchez JC, et al. Two-dimensional gel electrophoresis for proteome projects: the effects of protein hydrophobicity and copy number. Electrophoresis 1998; 19: 1501-1505.
34. Lepedda AJ, Cigliano A, Cherchi GM, et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 2009; 203: 112-118.
35. Urbonavicius S, Lindholt JS, Vorum H, et al. Proteomic identification of differentially expressed proteins in aortic wall of patients with ruptured and nonruptured abdominal aortic aneurysms. J Vasc Surg 2009; 49: 455-463.
36. Dupont A, Corseaux D, Dekeyzer O, et al. The proteome and secretome of human arterial smooth muscle cells. Proteomics 2005; 5: 585-596.
37. Barderas MG, Tunon J, Darde VM, et al. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J Proteome Res 2007; 6: 876-886.
38. Sung HJ, Ryang YS, Jang SW, et al. Proteomic analysis of differential protein expression in atherosclerosis. Biomarkers 2006; 11: 279-290.
39. Lilley KS, Friedman DB. All about DIGE: quantification technology for differential- display 2D-gel proteomics. Expert Rev Proteomics 2004; 1: 401-409.
40. Gustin C, Delaive E, Dieu M, et al. Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler Thromb Vasc Biol 2008; 28: 491-497.
41. Chen EI, Yates JR, 3rd. Cancer proteomics by quantitative shotgun proteomics. Mol Oncol 2007; 1: 144-159.
42. Lu B, McClatchy DB, Kim JY, et al. Strategies for shotgun identification of integral membrane proteins by tandem mass spectrometry. Proteomics 2008; 8: 3947-3955.
43. Wilm M, Mann M. Analytical properties of the nanoelectrospray ion source. Anal Chem 1996; 68: 1-8.
44. Peng J, Gygi SP. Proteomics: the move to mixtures. J Mass Spectrom 2001; 36: 1083-1091.
45. Scigelova M, Makarov A. Orbitrap mass analyzer--overview and applications in proteomics. Proteomics 2006; 6 (Suppl 2): 16-21.
46. Bergquist J. FTICR mass spectrometry in proteomics. Curr Opin Mol Ther 2003; 5: 310-314.
47. Blackburn K, Goshe MB. Challenges and strategies for targeted phosphorylation site identification and quantification using mass spectrometry analysis. Brief Funct Genomic Proteomic 2009; 8: 90-103.
48. Blackburn K, Mbeunkui F, Mitra SK, et al. Improving protein and proteome coverage through data-independent multiplexed peptide fragmentation. J Proteome Res 2010; 9: 3621-3637.
49. Bagnato C, Thumar J, Mayya V, et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics 2007; 6: 1088-1102.
50. Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot 2006; 57: 1501-1508.
51. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 17: 994-999.
52. Emadali A, Gallagher-Gambarelli M. Quantitative proteomics by SILAC: practicalities and perspectives for an evolving approach. Med Sci (Paris) 2009; 25: 835-842.
53. Ong SE, Foster LJ, Mann M. Mass spectrometric-based approaches in quantitative proteomics. Methods 2003; 29: 124-130.
54. Lutfalla G, Uze G. Performing quantitative reverse-transcribed polymerase chain reaction experiments. Methods Enzymol 2006; 410: 386-400.
55. Schwarz M, Spath L, Lux CA, et al. Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity. Thromb Haemost 2008; 100: 110-118.
56. Guo Y, Singleton PA, Rowshan A, et al. Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. Mol Cell Proteomics 2007; 6: 689-696.
57. Gasparri C, Curcio A, Torella D, et al. Proteomics reveals high levels of vitamin D binding protein in myocardial infarction. Front Biosci (Elite Ed) 2010; 2: 796-804.
58. Huttenhain R, Malmstrom J, Picotti P, et al. Perspectives of targeted mass spectrometry for protein biomarker verification. Curr Opin Chem Biol 2009; 13: 518-525.
59. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006; 5: 573-588.
60. Pan S, Aebersold R, Chen R, et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 2009; 8: 787-797.
61. Kay RG, Gregory B, Grace PB, et al. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun Mass Spectrom 2007; 21: 2585-2593.
62. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005; 563: 23-60.
63. Chaurand P, Schwartz SA, Reyzer ML, et al. Imaging mass spectrometry: principles and potentials. Toxicol Pathol 2005; 33: 92-101.
64. Chaurand P, Stoeckli M, Caprioli RM. Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry. Anal Chem 1999; 71: 5263-5270.
65. Reyzer ML, Caprioli RM. MALDI-MS-based imaging of small molecules and proteins in tissues. Curr Opin Chem Biol 2007; 11: 29-35.
66. Franck J, Arafah K, Elayed M, et al. MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol Cell Proteomics 2009; 8: 2023-2033.
67. Chaurand P, Schwartz SA, Billheimer D, et al. Integrating histology and imaging mass spectrometry. Anal Chem 2004; 76: 1145-1155.
68. Chaurand P, Caprioli RM. Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis 2002; 23: 3125-3135.
69. Dreisewerd K. The desorption process in MALDI. Chem Rev 2003; 103: 395-426.
70. Seeley EH, Oppenheimer SR, Mi D, et al. Enhancement of protein sensitivity for MALDI imaging mass spectrometry after chemical treatment of tissue sections. J Am Soc Mass Spectrom 2008; 19: 1069-1077.
71. Lemaire R, Wisztorski M, Desmons A, et al. MALDI-MS direct tissue analysis of proteins: Improving signal sensitivity using organic treatments. Anal Chem 2006; 78: 7145-7153.
72. Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry--looking beyond classical histology. Nat Rev Cancer 2010; 10: 639-646.
73. Chaurand P, Schriver KE, Caprioli RM. Instrument design and characterization for high resolution MALDI-MS imaging of tissue sections. J Mass Spectrom 2007; 42: 476-489.
74. Setou M, Sugiura Y. Guide to Planning the Sample Preparation Step. Imaging Mass Spectrometry. Springer Japan; 2010; pp. 11-30.
75. MacAleese L, Stauber J, Heeren RM. Perspectives for imaging mass spectrometry in the proteomics landscape. Proteomics 2009; 9: 819-834.
76. Groseclose MR, Andersson M, Hardesty WM, et al. Identification of proteins directly from tissue: in situ tryptic digestions coupled with imaging mass spectrometry. J Mass Spectrom 2007; 42: 254-262.
77. Grey AC, Gelasco AK, Section J, et al. Molecular morphology of the chick heart visualized by MALDI imaging mass spectrometry. Anat Rec (Hoboken) 2010; 293: 821-828.
78. Chaurand P, Norris JL, Cornett DS, et al. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J Proteome Res 2006; 5: 2889-2900.
79. Jurchen JC, Rubakhin SS, Sweedler JV. MALDI-MS imaging of features smaller than the size of the laser beam. J Am Soc Mass Spectrom 2005; 16: 1654-1659.
80. Stauber J, Lemaire R, Franck J, et al. MALDI imaging of formalin-fixed paraffinembedded tissues: application to model animals of Parkinson disease for biomarker hunting. J Proteome Res 2008; 7: 969-978.
81. Groseclose MR, Massion PP, Chaurand P, et al. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008; 8: 3715-3724.
82. Lemaire R, Desmons A, Tabet JC, et al. Direct analysis and MALDI imaging of formalin- fixed, paraffin-embedded tissue sections. J Proteome Res 2007; 6: 1295-1305.
83. Aoki Y, Toyama A, Shimada T, et al. A novel method for analyzing formalin-fixed paraffin embedded (FFPE) tissue sections by mass spectrometry imaging. Proceedings of the Japan Academy, Series B 2007; 83: 205-214.
84. Stauber J, MacAleese L, Franck J, et al. On-tissue protein identification and imaging by MALDI-ion mobility mass spectrometry. J Am Soc Mass Spectrom 2010; 21: 338-347.
85. Goodacre R, Vaidyanathan S, Dunn WB, et al. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004; 22: 245-252.
86. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130: 606-625.
87. Dunn WB, Ellis DI. Metabolomics: Current analytical platforms and methodologies. Trends Analyt Chem 2005; 24: 285-294.
88. Ekroos K, Janis M, Tarasov K, et al. Lipidomics: a tool for studies of atherosclerosis. Curr Atheroscler Rep 2010; 12: 273-281.
89. Goonewardena SN, Prevette LE, Desai AA. Metabolomics and atherosclerosis. Curr Atheroscler Rep 2010; 12: 267-272.
90. Guillarme D, Ruta J, Rudaz S, et al. New trends in fast and high-resolution liquid chromatography: a critical comparison of existing approaches. Anal Bioanal Chem 2010; 397: 1069-1082.
91. Mesaros C, Lee SH, Blair IA. Targeted quantitative analysis of eicosanoid lipids in biological samples using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 2736-2745.
92. Food and Drug Administration of the United States. Guidance for Industry-Bioanalytical Method Validation. US Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001. Available at: http://www/fda.gov/cder/guidance/index.htm
93. Tsikas D. A proposal for comparing methods of quantitative analysis of endogenous compounds in biological systems by using the relative lower limit of quantification (rLLOQ). J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 2244-2251.
94. van de Merbel NC. Quantitative determination of endogenous compounds in biological samples using chromatographic techniques. Trends Analyt Chem 2008; 27: 924-933.
95. Thomas A, Hopfgartner G, Giroud C, et al. Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun Mass Spectrom 2009; 23: 629-638.
96. Williams J, Wood J, Pandarinathan L, et al. Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization- MS. Anal Chem 2007; 79: 5582-5593.
97. Richardson D, Ortori CA, Chapman V, et al. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatographytandem electrospray ionization mass spectrometry. Anal Biochem 2007; 360: 216-226.
98. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-411.
99. Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74: 486-496.
100. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 2009; 31: 63-77.
101. Hiley CR. Endocannabinoids and the heart. J Cardiovasc Pharmacol 2009; 53: 267-276.
102. Mach F, Steffens S. The role of the endocannabinoid system in atherosclerosis. J Neuroendocrinol 2008; 20 (Suppl 1): 53-57.
103. Montecucco F, Matias I, Lenglet S, et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009; 205: 433-441.
104. Sugamura K, Sugiyama S, Nozaki T, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119: 28-36.
105. Gross RW, Han X. Shotgun lipidomics of neutral lipids as an enabling technology for elucidation of lipid-related diseases. Am J Physiol Endocrinol Metab 2009; 297: E297-303.
106. Han X, Gross RW. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev 2005; 24: 367-412.
107. Stahlman M, Ejsing CS, Tarasov K, et al. High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 2664-2672.
108. Ejsing CS, Duchoslav E, Sampaio J, et al. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal Chem 2006; 78: 6202-6214.
109. Schwudke D, Oegema J, Burton L, et al. Lipid profiling by multiple precursor and neutral loss scanning driven by the data-dependent acquisition. Anal Chem 2006; 78: 585-595.
110. Han X, Jiang X. A review of lipidomic technologies applicable to sphingolipidomics and their relevant applications. Eur J Lipid Sci Technol 2009; 111: 39-52.
111. McAnoy AM, Wu CC, Murphy RC. Direct qualitative analysis of triacylglycerols by electrospray mass spectrometry using a linear ion trap. J Am Soc Mass Spectrom 2005; 16: 1498-1509.
112. Liebisch G, Binder M, Schifferer R, et al. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim Biophys Acta 2006; 1761: 121-128.
113. Herzog R, Schwudke D, Schuhmann K, et al. A novel informatics concept for high-throughput shotgun lipidomics based on the molecular fragmentation query language. Genome Biol 2011; 12: R8.
114. Han X, Yang J, Cheng H, et al. Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry 2005; 44: 16684-16694.
115. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
116. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics--a review in human disease diagnosis. Anal Chim Acta 2010; 659: 23-33.
117. Vallejo M, Garcia A, Tunon J, et al. Plasma fingerprinting with GC-MS in acute coronary syndrome. Anal Bioanal Chem 2009; 394: 1517-1524.
118. Zhang F, Jia Z, Gao P, et al. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta 2009; 79: 836-844.
119. Bergheanu SC, Reijmers T, Zwinderman AH, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin 2008; 24: 2477-2487.
120. Laaksonen R, Katajamaa M, Paiva H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statininduced changes in muscle. PLoS One 2006; 1: e97.
121. Schwudke D, Hannich JT, Surendranath V, et al. Top-down lipidomic screens by multivariate analysis of high-resolution survey mass spectra. Anal Chem 2007; 79: 4083-4093.
122. Thomas A, Deglon J, Lenglet S, et al. High-Throughput Phospholipidic Fingerprinting by Online Desorption of Dried Spots and Quadrupole-Linear Ion Trap Mass Spectrometry: Evaluation of Atherosclerosis Biomarkers in Mouse Plasma. Anal Chem 2010; 82: 6687-6694.
123. Graessler J, Schwudke D, Schwarz PE, et al. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 2009; 4: e6261.
124. Chaurand P, Cornett DS, Angel PM, et al. From Whole-body Sections down to Cellular Level, Multiscale Imaging of Phospholipids by MALDI Mass Spectrometry. Mol Cell Proteomics 2011; 10: O110.004259.
125. Meriaux C, Franck J, Wisztorski M, et al. Liquid ionic matrixes for MALDI mass spectrometry imaging of lipids. J Proteomics 2010; 73: 1204-1218.
126. Sugiura Y, Setou M. Selective imaging of positively charged polar and nonpolar lipids by optimizing matrix solution composition. Rapid Commun Mass Spectrom 2009; 23: 3269-3278.
127. Taira S, Sugiura Y, Moritake S, et al. Nanoparticle-assisted laser desorption/ionization based mass imaging with cellular resolution. Anal Chem 2008; 80: 4761-4766.
128. Puolitaival SM, Burnum KE, Cornett DS, et al. Solvent-free matrix dry-coating for MALDI imaging of phospholipids. J Am Soc Mass Spectrom 2008; 19: 882-886.
129. Hankin JA, Barkley RM, Murphy RC. Sublimation as a method of matrix application for mass spectrometric imaging. J Am Soc Mass Spectrom 2007; 18: 1646-1652.
130. Sugiura Y, Konishi Y, Zaima N, et al. Visualization of the cell-selective distribution of PUFA-containing phosphatidylcholines in mouse brain by imaging mass spectrometry. J Lipid Res 2009; 50: 1776-1788.
131. Garrett TJ, Yost RA. Tandem mass spectrometric methods for phospholipid analysis from brain tissue. Methods Mol Biol 2010; 656: 209-230.
132. Shimma S, Sugiura Y, Hayasaka T, et al. Mass imaging and identification of biomolecules with MALDI-QIT-TOF-based system. Anal Chem 2008; 80: 878-885.
133. Woods AS, Jackson SN. The application and potential of ion mobility mass spectrometry in imaging MS with a focus on lipids. Methods Mol Biol 2010; 656: 99-111.
134. McLean JA, Ridenour WB, Caprioli RM. Profiling and imaging of tissues by imaging ion mobility-mass spectrometry. J Mass Spectrom 2007; 42: 1099-1105.
135. Landgraf RR, Prieto Conaway MC, Garrett TJ, et al. Imaging of lipids in spinal cord using intermediate pressure matrix-assisted laser desorption-linear ion trap/Orbitrap MS. Anal Chem 2009; 81: 8488-8495.
136. Cornett DS, Frappier SL, Caprioli RM. MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue. Anal Chem 2008; 80: 5648-5653.
137. AV. Why is SIMS underused in chemical and biological analysis? Challenges and opportunities. Anal Chem 2008; 80: 8865-8870.
138. Colliver TL, Brummel CL, Pacholski ML, et al. Atomic and molecular imaging at the single-cell level with TOF-SIMS. Anal Chem 1997; 69: 2225-2231.
139. Heien ML, Piehowski PD, Winograd N, et al. Lipid detection, identification, and imaging single cells with SIMS. Methods Mol Biol 2010; 656: 85-97.
140. Todd PJ, Schaaff TG, Chaurand P, et al. Organic ion imaging of biological tissue with secondary ion mass spectrometry and matrix-assisted laser desorption/ionization. J Mass Spectrom 2001; 36: 355-369.
141. Ostrowski SG, Kurczy ME, Roddy TP, et al. Secondary ion MS imaging to relatively quantify cholesterol in the membranes of individual cells from differentially treated populations. Anal Chem 2007; 79: 3554-3560.
142. Altelaar AF, van Minnen J, Jimenez CR, et al. Direct molecular imaging of Lymnaea stagnalis nervous tissue at subcellular spatial resolution by mass spectrometry. Anal Chem 2005; 77: 735-741.
143. Mas S, Touboul D, Brunelle A, et al. Lipid cartography of atherosclerotic plaque by cluster-TOF-SIMS imaging. Analyst 2007; 132: 24-26.
144. Manicke NE, Nefliu M, Wu C, et al. Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry. Anal Chem 2009; 81: 8702-8707.
145. Dill AL, Ifa DR, Manicke NE, et al. Mass spectrometric imaging of lipids using desorption electrospray ionization. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 2883-2889.
146. Manisali I, Chen DDY, Schneider BB. Electrospray ionization source geometry for mass spectrometry: past, present, and future. Trends Analyt Chem 2006; 25: 243-256.
147. Kertesz V, Van Berkel GJ. Improved imaging resolution in desorption electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 2639-2644.